2019 International Congress Archives - Page 122 of 217

Management of Patients with Functional Movement Disorders: A Transcultural Perspective

C. Maurer, D. Anderson, A. Asadi-Pooya, J. Baizabal, M. Damianova, C. Ganos, R. Kanaan, M. Tijssen, J. Kwasa, I. Moreno, S. Pandey, JE. Park, D. Saylor, M. Stamelou, C. Stephen, T. Teodoro, M. Tinazzi, K. Lafaver (Stony Brook, NY, USA)
Management of poor response to Botulinum toxin in cervical dystonia: a multicentre audit

H. Tucker, F. Osei-Poku, D. Ashton, R. Lally, J. Alty, C. Kobylecki (Salford, United Kingdom)
Mandibular Advancement Device in Parkinson’s disease: an efficacious and usable device in a disabling disease

V. Cochen Decock, M. Castel, I. Bonafé (Montpellier, France)
MCI reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease

SJ. Chung, Y-H. Park, YH. Sohn, J-M. Lee, PH. Lee (Seoul, Republic of Korea)
MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs

R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto (New York, NY, USA)
MDS Translation Program for MDS-UPDRS and UDysRS

S. Luo, N. Lapelle, P. Martin, C. Goetz, G. Stebbins (Durham, NC, USA)
MDS-UPDRS Part III predictors of Part II Item Scores in PPMI

J. Cedarbaum, Z. Xiao, M. Yang (Cambridge, MA, USA)
Measurement properties of the MDS-NMS Non-motor Fluctuations Subscale

MJ. Forjaz, A. Ayala, C. Rodriguez-Blazquez, A. Schrag, D. Weintraub, A. Rizos, KR. Chaudhuri, P. Martinez-Martin (Philadelphia, PA, USA)
Measuring cognitive decline in PD-MCI patients with high level education: Do we have the appropriate tools?

L. Mentzer, A. Richardson, T. Nevo, S. Meyer, S. Rosenblum, N. Gemerman, S. Hassin-Baer, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, G. Yahalom (Ramat-Gan, Israel)
Measuring disease progression with neuroimaging in MSA-a systematic review

B. Heim, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)